April 10, 2017 Bio/Pharma/CRO M&A, Partnerships Product Launch

GE Healthcare acquires Asymptote for complete, digitally-enabled cryogenic cold chain technology supporting safe manufacture and delivery of cellular therapies

Chalfont St Giles, UK – 11 April 2017 – GE Healthcare has acquired Asymptote Limited, specialists in cryochain technology for sensitive cellular therapies. Asymptote’s integrated suite of cryochain hardware, software and consumables are designed to maintain the potency of cellular therapies enabling ultra-low temperature freezing during production, all the way to thawing at the clinic... Read more

April 10, 2017 Environ, Ag./Food & Bev

2016: A Strong Year for the Greiner Group (copy 1)

The Greiner Group once again improved its sales figures and reached its financial targets in the business year 2016. Besides globalization, diversification and innovation as the key factors of success, the “Plastics for Life” sustainability strategy is at the center of activities. Kremsmünster, May 3, 2017 – The Greiner Group improved its consolidated sales revenues... Read more

April 10, 2017 Liq. Handling & Robotics M&A, Partnerships

GE Healthcare invests in Zenith Technologies, the companies to deliver together next-generation of biopharma automation

CHALFONT ST. GILES, UK and CORK, IRELAND – 11 April 2017 – Zenith Technologies and GE Healthcare Life Sciences announce today that GE has completed a strategic minority investment in Irish-owned Zenith Technologies, a leading technology company delivering manufacturing software systems and solutions for the life sciences industry. This enhancement of the existing partnership brings... Read more

April 10, 2017 Bio/Pharma/CRO PR/Corporate

Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer

Basel, 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared... Read more

April 7, 2017 Clinical Research/Diagn. M&A, Partnerships

VWR Acquires MESM Ltd.

Acquisition further expands VWRCATALYST Services for Clinical Trial Studies RADNOR, Pa., April 7, 2017 /PRNewswire/ — VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today that it has acquired MESM Ltd., a provider of laboratory and medical equipment and ancillary supplies to clinical trials... Read more